Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 238.9% in November

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 105,400 shares, a growth of 238.9% from the October 31st total of 31,100 shares. Based on an average trading volume of 74,600 shares, the short-interest ratio is currently 1.4 days. Currently, 2.8% of the shares of the stock are short sold.

Altamira Therapeutics Stock Down 4.5 %

Shares of CYTO traded down $0.02 during mid-day trading on Thursday, hitting $0.40. 56,414 shares of the stock were exchanged, compared to its average volume of 724,693. The firm has a 50-day moving average of $0.56 and a two-hundred day moving average of $0.96. Altamira Therapeutics has a 52-week low of $0.40 and a 52-week high of $17.20.

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.